Method for analyzing tumor mutation load based on high-flux targeted sequencing
A mutation load, high-throughput technology, applied in the direction of biochemical equipment and methods, microbial determination/inspection, specific-purpose bioreactor/fermenter, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0067] Example 1. High-throughput targeted sequencing and TMB analysis (OncoScreenPlus TMB)
[0068] 1. Pretreatment and DNA extraction of tumor tissue samples and paired control samples
[0069] In this embodiment, as the tumor tissue sample, samples with tumor cells accounting for ≥ 20% are used, and paracancerous tissue or blood leukocyte samples are selected as paired normal (control) samples. The DNA extraction process of tumor tissue samples and control samples was carried out according to the operating instructions provided with the kit (QIAamp DNA FFPE Tissue Kit, produced by QIAGEN). Subsequently, the extracted DNA was fragmented into DNA fragments with an average of about 200 bp, and used to establish a pre-library. If not used immediately for library construction, store the fragmented DNA in a -20°C freezer.
[0070] 2. Pre-library Preparation
[0071] The methodology used in the preparation of the pre-library is the classic ultrasound-interrupted double-strand l...
Embodiment 2
[0086] Example 2. TMB Detection and Evaluation of Clinical Tumor Samples
[0087] This embodiment includes 44 cases of stage IV non-small cell lung cancer samples from the top three hospitals in China (14 samples from the First Affiliated Hospital of Zhejiang University School of Medicine, and 30 samples from the Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology) and paired samples. White blood cell samples were tested for TMB. 44 samples were used to perform WES and Target capture sequencing on tumor samples using Agilent SureSelectXT HumanAll Exon V5 (detected by Mingcode (Shanghai) Biotechnology Co., Ltd.) and the method disclosed herein. Taking the gold standard WES TMB calculated by TMB as the evaluation standard, the correlation between TMB (OncoScreenPlus TMB) calculated by the disclosed method and WES TMB = 0.841, R2 = 0.707, such as figure 2 shown. The TMB cut-off value reported in the literature is 7.4 [1] , 9.65...
Embodiment 3I
[0090] Example 3.In silico TMB detection and evaluation
[0091]This example adopts in silico methodology to evaluate the consistency between OncoScreenPlus TMB and WES TMB. Specifically, the data MAF files of TCGA MC3 samples, including 32 cancers, were downloaded from the database website of the National Institutes of Health (NIH) (https: / / gdc.cancer.gov / about-data / publications / mc3-2017) The mutation data of 8291 cases of samples are shown in Table 3. Refer to the FoCR (Friends of Cancer Research) WES TMB standard to calculate the WES TMB: (1) FILTER! ="PASS" mutations are defined as false positives (variant artifacts), remove samples containing more than 50% of false positive mutations; (2) remove false positive mutations in samples; (3) remove mutation sequences (variantcount)<3 Mutation; (4) remove mutations with allele frequency (allele frequency) <5%; (5) remove mutations with total depth (total depth) <25; (6) select mutations in coding regions (about 32.3Mb) in CCDS...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com